Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
21 juin 2022 16h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob...
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
05 mai 2022 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In...
ARCA biopharma Announces First Quarter 2022 Financial Results
02 mai 2022 16h15 HE
|
ARCA biopharma, Inc.
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE...
ARCA biopharma Establishes Special Committee of the Board of Directors
18 avr. 2022 16h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial
31 mars 2022 16h15 HE
|
ARCA biopharma, Inc.
For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for...
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
14 mars 2022 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
04 janv. 2022 08h30 HE
|
ARCA biopharma, Inc.
Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important...
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
02 déc. 2021 08h30 HE
|
ARCA biopharma, Inc.
Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company...
ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
09 nov. 2021 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
02 nov. 2021 16h15 HE
|
ARCA biopharma, Inc.
On-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with...